Matthew V Holt
7PUBLICATIONS
52CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.Anran Chen, Beom-Jun Kim, Aparna Mitra
|Aug 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.Junkai Wang, Alexander B Saltzman, Eric J Jaehnig
|Jul 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.Beom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei
|Apr 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Xuxu Gou, Beom-Jun Kim, Meenakshi Anurag
|Jun 27, 2018
Early butyrate induced acetylation of histone H4 is proteoform specific and linked to methylation state.Tao Wang, Matthew V Holt, Nicolas L Young
|Jun 09, 2018
The histone H4 proteoform dynamics in response to SUV4-20 inhibition reveals single molecule mechanisms of inhibitor resistance.Tao Wang, Matthew V Holt, Nicolas L Young
Pageof 2
Frequent Collaborators
4 joint publications
Beom-Jun Kim
4 joint publications
Meenakshi Anurag
4 joint publications
Jonathan T Lei
4 joint publications
Matthew J Ellis
3 joint publications
Nicolas L Young
3 joint publications
Diana Fandino
2 joint publications
Tao Wang
2 joint publications
Xuxu Gou
2 joint publications
Meggie N Young
2 joint publications
Craig T Vollert
